Trial
NCT01924858
A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Alzheimer's Disease
Intervention
GSK2647544 oral
Why stopped
Study objectives met so study concluded earlier than planned hence we terminated the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-09